Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
146 participants
INTERVENTIONAL
2012-12-31
2013-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Fibrin Glue After ESD for High Risk Patients of Bleeding
NCT04602689
Role of Hemostatic Powder (Endo-clotTM) in Success and Prevention of Bleeding Within Gastric Cancer Patients With Bleeding
NCT02732483
Role of Hemostatic Powder (Endo-clotTM) in Prevention of Bleeding Within High Risk Patients After ESD
NCT02625792
Efficacy of Hemostatic Powder in Preventing Bleeding After Gastric Endoscopic Submucosal Dissection in High-risk Patients: A Prospective Randomized Control Study
NCT03169569
Healing Effects of Autologous Platelet Rich Plasma on Gastric Ulcer Caused by Endoscopic Submucosal Dissection
NCT03220334
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
* Scheduled for ESD (2) Exclusion: Coagulopathy- liver cirrhosis, thrombocytopenia
* Anti-platelet agents
2. Method
(1) Study group: combination with Surgicel® Fibrillar and H2RA (2) Control group: monotherapy with PPI 3. Sample size : 157 4. Result
1. Primary endpoint: rate of delayed bleeding after ESD
2. Secondary endpoint: follow-up hemoglobin after ESD
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
PREVENTION
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
combination therapy of H2RA and surgicel
H2RA and surgicel
H2RA and surgicel
combination therapy of H2RA and surgicel
Monotherapy of PPI
PPI
PPI
monotherapy of PPI
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
PPI
monotherapy of PPI
H2RA and surgicel
combination therapy of H2RA and surgicel
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Anti-platelet agents
20 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Soonchunhyang University Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Su Jin Hong
MD, PhD
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Digestive Disease Center, Department of Internal Medicine, Soonchunhyang University College of Medicine
Bucheon-si, Gyeonggi-do, South Korea
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
MD_SCHBC_IRB_2012-06
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.